Genmab

Genmab. Genmab is a leading international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer and other serious diseases. Founded in 1999, the company is headquartered in Copenhagen, Denmark, and is publicly listed on the Nasdaq Copenhagen and the Nasdaq Global Select Market in the United States. Its innovative pipeline and strategic partnerships with major pharmaceutical firms have established it as a key player in the field of oncology and immunology.

History

Genmab was established in 1999 by Florian Schönharting and was among the first European companies to focus exclusively on fully human monoclonal antibody technologies. A pivotal early investment came from the Danish pharmaceutical company Lundbeck, providing crucial seed funding. The company's initial public offering on the Copenhagen Stock Exchange in 2000 and a subsequent listing on the Nasdaq in the United States provided the capital to advance its proprietary platforms. Key milestones include the 2006 FDA approval of ofatumumab (Arzerra), its first co-developed product, and the transformative 2015 partnership with Janssen Biotech for daratumumab (Darzalex), which became a blockbuster therapy for multiple myeloma. This success fueled significant expansion of its research facilities and global footprint.

Technology and platforms

The company's research and development engine is powered by several proprietary and next-generation technology platforms designed to create differentiated antibody-based medicines. Its foundational HuMab-Mouse technology, developed in collaboration with Medarex, generates fully human monoclonal antibodies. The DuoBody platform enables the creation of bispecific antibodies, which can engage two different targets simultaneously, such as tumor cells and immune cells. The HexaBody platform is engineered to enhance antibody-dependent cellular cytotoxicity (ADCC), a key immune mechanism. More recent innovations include the DuoHexaBody and HexElect platforms, which combine aspects of bispecificity and enhanced effector function to create potent therapeutic candidates for challenging diseases.

Key products and partnerships

Genmab's portfolio features several marketed and pipeline assets, primarily developed through strategic alliances. Its most significant product is daratumumab (Darzalex), developed with Janssen Biotech, which is approved for multiple myeloma and light chain amyloidosis and has achieved multi-billion dollar annual sales. Another major product is epcoritamab (Epkinly/Tepkinly), a bispecific antibody developed with AbbVie for diffuse large B-cell lymphoma and follicular lymphoma. Other notable partnerships include collaborations with Seagen (now part of Pfizer) for tisotumab vedotin (Tivdak) in cervical cancer, and with BioNTech and Gilead Sciences on various oncology programs. These alliances leverage the company's technological expertise while sharing development costs and commercialization efforts.

Financial performance and business model

The company operates a capital-efficient business model centered on royalties and milestone payments from its partnered programs, supplemented by co-commercialization profits on certain products. This strategy has resulted in robust and growing revenue streams, primarily driven by royalties on the global net sales of daratumumab. The company has consistently reported strong financial results, with significant year-over-year revenue growth and profitability, allowing for substantial reinvestment in its internal pipeline and technology platforms. Its financial strength is reflected in its market capitalization, making it one of the largest biotechnology companies in Europe.

Corporate affairs and leadership

The company is led by President and Chief Executive Officer Jan van de Winkel, a co-founder who has guided its scientific and strategic direction since its inception. Its operational headquarters are in Copenhagen, with important research sites in Utrecht in the Netherlands and Princeton, New Jersey. The corporate culture emphasizes scientific innovation, integrity, and a commitment to improving patient lives. It actively engages in various corporate social responsibility initiatives and maintains a board of directors with extensive experience in the global pharmaceutical industry and financial markets.

Category:Biotechnology companies of Denmark Category:Companies listed on Nasdaq Copenhagen Category:Pharmaceutical companies established in 1999